/ANIX
ANIX Stock - Anixa Biosciences, Inc.
Healthcare|BiotechnologyNASDAQ
$3.30+1.85%
+$0.06 (+1.85%) • Dec 19
75
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.39
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+203.0%upside
Target: $10.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ANIX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.27 – $3.33
TARGET (TP)$10.00
STOP LOSS$3.04
RISK/REWARD1:25.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.50
52W High$5.46
52W Low$2.07
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $210,000 | $2.47B | $512,500 | N/A |
| Gross Profit | $-37,000 | $49,000 | $2.47B | $127,498 | $-90,157 |
| Gross Margin | N/A | 23.3% | 100.0% | 24.9% | N/A |
| Operating Income | $-13,831,000 | $-11,011,000 | $-13,875,000 | $-13,135,692 | $-9,978,202 |
| Net Income | $-12,554,000 | $-9,811,000 | $-13,491,000 | $-12,946,631 | $-10,132,516 |
| Net Margin | N/A | -4671.9% | -0.5% | -2526.2% | N/A |
| EPS | $-0.39 | $-0.32 | $-0.44 | $-0.45 | $-0.46 |
Company Overview
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$9
Average Target
↑ 172.7% Upside
Now
$8
Low
$9
Average
$10
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| March 21st 2025 | Maxim Group | Initiation | Buy | $10 |
| December 23rd 2022 | Chardan Capital Markets | Initiation | Buy | $8 |
Earnings History & Surprises
ANIXBeat Rate
71%
Last 17 quarters
Avg Surprise
+9.1%
EPS vs Estimate
Beats / Misses
12/2
3 met exactly
Latest EPS
$-0.07
Q3 2025
EPS Surprise History
Q1 24
0.0%
$-0.09vs$-0.09
Q1 24
-11.1%
$-0.10vs$-0.09
Q2 24
+9.1%
$-0.10vs$-0.11
Q3 24
+9.1%
$-0.10vs$-0.11
Q1 25
+18.2%
$-0.09vs$-0.11
Q1 25
0.0%
$-0.10vs$-0.10
Q2 25
+10.0%
$-0.09vs$-0.10
Q3 25
+30.0%
$-0.07vs$-0.10
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 26, 2026 | — | — | — | — |
Q1 2026 | Jan 9, 2026 | $-0.09 | — | — | — |
Q3 2025 | Sep 10, 2025 | $-0.10 | $-0.07 | +30.0% | ✓ BEAT |
Q2 2025 | May 28, 2025 | $-0.10 | $-0.09 | +10.0% | ✓ BEAT |
Q1 2025 | Mar 11, 2025 | $-0.10 | $-0.10 | 0.0% | = MET |
Q1 2025 | Jan 10, 2025 | $-0.11 | $-0.09 | +18.2% | ✓ BEAT |
Q3 2024 | Sep 6, 2024 | $-0.11 | $-0.10 | +9.1% | ✓ BEAT |
Q2 2024 | Jun 4, 2024 | $-0.11 | $-0.10 | +9.1% | ✓ BEAT |
Q1 2024 | Mar 12, 2024 | $-0.09 | $-0.10 | -11.1% | ✗ MISS |
Q1 2024 | Jan 16, 2024 | $-0.09 | $-0.09 | 0.0% | = MET |
Q3 2023 | Sep 6, 2023 | $-0.09 | $-0.08 | +11.1% | ✓ BEAT |
Q2 2023 | Jun 14, 2023 | $-0.11 | $-0.07 | +36.4% | ✓ BEAT |
Q1 2023 | Mar 16, 2023 | $-0.16 | $-0.08 | +50.0% | ✓ BEAT |
Q1 2023 | Jan 4, 2023 | $-0.13 | $-0.12 | +7.7% | ✓ BEAT |
Q3 2022 | Sep 9, 2022 | $-0.13 | $-0.09 | +30.8% | ✓ BEAT |
Q2 2022 | Jun 10, 2022 | $-0.13 | $-0.12 | +7.7% | ✓ BEAT |
Q1 2022 | Mar 11, 2022 | $-0.13 | $-0.13 | 0.0% | = MET |
Q1 2022 | Jan 4, 2022 | — | $-0.13 | — | — |
Q3 2021 | Sep 1, 2021 | $-0.08 | $-0.14 | -75.0% | ✗ MISS |
Q2 2021 | Jun 10, 2021 | $-0.10 | $-0.08 | +20.0% | ✓ BEAT |
Latest News
Anixa Biosciences Completes The Transfer Of The Investigational New Drug Application For Breast Cancer Vaccine, Preparing For Phase 2 Trials
📈 PositiveBenzinga•Dec 15, 2025, 01:47 PM
D. Boral Capital Maintains Buy on Anixa Biosciences, Maintains $10 Price Target
📈 PositiveBenzinga•Dec 12, 2025, 12:23 PM
Reported Earlier, Anixa Biosciences Announces Phase 1 Breast Cancer Vaccine Data With Primary Endpoints Met And Immune Response Observed In 74% Of Participants
📈 PositiveBenzinga•Dec 12, 2025, 08:29 AM
Anixa Biosciences Announces World Health Organization Of 'liraltagene autoleucel' As Non-Proprietary Name Of Its CAR-T Therapy
➖ NeutralBenzinga•Nov 17, 2025, 01:17 PM
Anixa Biosciences Awarded US Patent Covering Aspects Of Co.'s Breast Cancer Technology
📈 PositiveBenzinga•Nov 12, 2025, 02:02 PM
Anixa Biosciences Executes Data Transfer Agreement With Cleveland Clinic As Key Step In IND Transfer For Upcoming Phase 2 Breast Cancer Vaccine Clinical Trial
📈 PositiveBenzinga•Nov 5, 2025, 02:01 PM
ANIX stock has given up its prior gain. Anixa Biosciences shares were trading higher after the company announced the issuance of a Chinese patent covering its breast cancer vaccine technology.
➖ NeutralBenzinga•Oct 20, 2025, 02:31 PM
Anixa Biosciences shares are trading higher after the company announced the issuance of a Chinese patent covering its breast cancer vaccine technology.
📈 PositiveBenzinga•Oct 20, 2025, 12:27 PM
Anixa Announces That The Chinese National Intellectual Property Administration Has Issued Patent Number ZL2020800215666, Covering Key Aspects Of The Company's Breast Cancer Vaccine Technology
📈 PositiveBenzinga•Oct 20, 2025, 12:27 PM
D. Boral Capital Maintains Buy on Anixa Biosciences, Maintains $10 Price Target
📈 PositiveBenzinga•Oct 7, 2025, 02:52 PM
Anixa Biosciences Completes The Final Patient Visit In Its Phase 1 Breast Cancer Vaccine Clinical Trial
📈 PositiveBenzinga•Oct 7, 2025, 12:46 PM
D. Boral Capital Maintains Buy on Anixa Biosciences, Maintains $10 Price Target
📈 PositiveBenzinga•Sep 22, 2025, 02:07 PM
Anixa To Present Phase 1 Breast Cancer Vaccine Data At 2025 San Antonio Breast Cancer Symposium
➖ NeutralBenzinga•Sep 22, 2025, 12:09 PM
HC Wainwright & Co. Reiterates Buy on Anixa Biosciences, Maintains $7 Price Target
📈 PositiveBenzinga•Sep 11, 2025, 10:19 AM
Anixa Biosciences Files For Mixed Shelf Of Up To $200M
➖ NeutralBenzinga•Sep 11, 2025, 12:06 AM
Anixa Biosciences Q3 EPS $(0.07) Beats $(0.09) Estimate
📈 PositiveBenzinga•Sep 10, 2025, 08:36 PM
D. Boral Capital Maintains Buy on Anixa Biosciences, Maintains $10 Price Target
📈 PositiveBenzinga•Sep 9, 2025, 12:38 PM
Anixa Biosciences Completes Dosing Of Fourth Cohort In Ongoing Phase 1 Clinical Trial Evaluating FSHR-Targeted CAR-T/CER-T Therapy For Recurrent Ovarian Cancer
📈 PositiveBenzinga•Sep 8, 2025, 12:09 PM
Anixa Biosciences Receives CNIPA Notice Of Allowance For Breast Cancer Vaccine Patent, Expanding Global IP Portfolio
📈 PositiveBenzinga•Aug 20, 2025, 12:42 PM
D. Boral Capital Maintains Buy on Anixa Biosciences, Maintains $10 Price Target
📈 PositiveBenzinga•Aug 19, 2025, 11:20 AM
Frequently Asked Questions about ANIX
What is ANIX's current stock price?
Anixa Biosciences, Inc. (ANIX) is currently trading at $3.30 per share. The stock has moved +1.85% today.
What is the analyst price target for ANIX?
The average analyst price target for ANIX is $10.00, based on 1 analyst.
What sector is Anixa Biosciences, Inc. in?
Anixa Biosciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ANIX's market cap?
Anixa Biosciences, Inc. has a market capitalization of $0.11 billion, making it a small-cap company.
Does ANIX pay dividends?
No, Anixa Biosciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABOS
Acumen Pharmaceuticals, Inc.
$2.15
Mkt Cap: $0.1B
ACTU
Actuate Therapeutics Inc
$6.98
Mkt Cap: $0.2B
AGEN
Agenus Inc.
$3.44
Mkt Cap: $0.1B
ENTX
Entera Bio Ltd.
$1.77
Mkt Cap: $0.1B
HURA
TuHURA Biosciences, Inc.
$0.82
Mkt Cap: $0.0B
INO
Inovio Pharmaceuticals, Inc.
$2.28
Mkt Cap: $0.1B
IRD
Opus Genetics, Inc.
$2.00
Mkt Cap: $0.1B
SEER
Seer, Inc.
$1.79
Mkt Cap: $0.1B
SPRO
Spero Therapeutics, Inc.
$2.32
Mkt Cap: $0.1B
VTGN
VistaGen Therapeutics, Inc.
$0.78
Mkt Cap: $0.0B
Explore stocks similar to ANIX for comparison